Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data

被引:119
作者
Accurso, Frank J. [1 ,8 ]
Van Goor, Fredrick [2 ]
Zha, Jiuhong [2 ]
Stone, Anne J. [2 ]
Dong, Qunming [2 ]
Ordonez, Claudia L. [2 ]
Rowe, Steven M. [3 ]
Clancy, John Paul [4 ]
Konstan, Michael W. [5 ]
Hoch, Heather E. [1 ,8 ]
Heltshe, Sonya L. [6 ,9 ]
Ramsey, Bonnie W. [6 ,9 ]
Campbell, Preston W. [7 ]
Ashlock, Melissa A. [7 ]
机构
[1] Univ Colorado Denver, Dept Pediat, Aurora, CO 80045 USA
[2] Vertex Pharmaceut Inc, Cambridge, MA 02139 USA
[3] Univ Alabama Birmingham, Birmingham, AL 35249 USA
[4] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45220 USA
[5] Case Western Reserve Univ, Sch Med, Dept Pediat, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA
[6] Univ Washington, Med Ctr, Seattle Childrens Hosp, Seattle, WA 98195 USA
[7] Cyst Fibrosis Fdn Therapeut, Bethesda, MD 20814 USA
[8] Univ Colorado Denver, Aurora, CO 80045 USA
[9] Seattle Childrens Hosp, Seattle, WA 98105 USA
关键词
Cystic fibrosis; Nasal potential difference; Variance; Sweat test; NASAL POTENTIAL DIFFERENCE; AIRWAY ION-TRANSPORT; CYSTIC-FIBROSIS; CHANNEL FUNCTION; REGULATOR GENE; IN-VITRO; MUTATION; DIAGNOSIS; PANCREATITIS; GUIDELINES;
D O I
10.1016/j.jcf.2013.09.007
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: We examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic fibrosis (CF) patients with a G551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference (NPD) to estimate CFTR activity. Methods: Sweat chloride and NPD were secondary endpoints in this placebo-controlled, Multicenter trial. Standardization of sweat collection, processing, and analysis was employed for the first time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity. Results: Within-patient sweat chloride determinations showed sufficient precision to detect differences between dose-groups and assess ivacaftor treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%-40% of normal. Conclusions: Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators. (C) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 31 条
[1]   Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation [J].
Accurso, Frank J. ;
Rowe, Steven M. ;
Clancy, J. P. ;
Boyle, Michael P. ;
Dunitz, Jordan M. ;
Durie, Peter R. ;
Sagel, Scott D. ;
Hornick, Douglas B. ;
Konstan, Michael W. ;
Donaldson, Scott H. ;
Moss, Richard B. ;
Pilewski, Joseph M. ;
Rubenstein, Ronald C. ;
Uluer, Ahmet Z. ;
Aitken, Moira L. ;
Freedman, Steven D. ;
Rose, Lynn M. ;
Mayer-Hamblett, Nicole ;
Dong, Qunming ;
Zha, Jiuhong ;
Stone, Anne J. ;
Olson, Eric R. ;
Ordonez, Claudia L. ;
Campbell, Preston W. ;
Ashlock, Melissa A. ;
Ramsey, Bonnie W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (21) :1991-2003
[2]   Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis [J].
Ahrens, RC ;
Standaert, TA ;
Launspach, J ;
Han, SH ;
Teresi, ME ;
Aitken, ML ;
Kelley, TJ ;
Hilliard, KA ;
Milgram, LJH ;
Konstan, MW ;
Weatherly, MR ;
McCarty, NA .
PEDIATRIC PULMONOLOGY, 2002, 33 (02) :142-150
[3]   Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial [J].
Alton, EWFW ;
Stern, M ;
Farley, R ;
Jaffe, A ;
Chadwick, SL ;
Phillips, J ;
Davies, J ;
Smith, SN ;
Browning, J ;
Davies, MG ;
Hodson, ME ;
Durham, SR ;
Li, D ;
Jeffery, PK ;
Scallan, M ;
Balfour, R ;
Eastman, SJ ;
Cheng, SH ;
Smith, AE ;
Meeker, D ;
Geddes, DM .
LANCET, 1999, 353 (9157) :947-954
[4]   DOES LITHIUM-CARBONATE AFFECT THE ION-TRANSPORT ABNORMALITY IN CYSTIC-FIBROSIS [J].
ANBAR, RD ;
LAPEY, A ;
KHAW, KT ;
SPRAGG, J ;
STRIEDER, DJ ;
SHAW, LF ;
KELLY, DH ;
SHANNON, DC .
PEDIATRIC PULMONOLOGY, 1990, 8 (02) :82-88
[5]   The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis [J].
Bishop, MD ;
Freedman, SD ;
Zielenski, J ;
Ahmed, N ;
Dupuis, A ;
Martin, S ;
Ellis, L ;
Shea, J ;
Hopper, I ;
Corey, M ;
Kortan, P ;
Haber, G ;
Ross, C ;
Tzountzouris, J ;
Steele, L ;
Ray, PN ;
Tsui, LC ;
Durie, PR .
HUMAN GENETICS, 2005, 118 (3-4) :372-381
[6]   Change in Sweat Chloride as a Clinical End Point in Cystic Fibrosis Clinical Trials The Ivacaftor Experience [J].
Durmowicz, Anthony G. ;
Witzmann, Kimberly A. ;
Rosebraugh, Curtis J. ;
Chowdhury, Badrul A. .
CHEST, 2013, 143 (01) :14-18
[7]   Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report [J].
Farrell, Philip M. ;
Rosenstein, Beryl J. ;
White, Terry B. ;
Accurso, Frank J. ;
Castellani, Carlo ;
Cutting, Garry R. ;
Durie, Peter R. ;
LeGrys, Vicky A. ;
Massie, John ;
Parad, Richard B. ;
Rock, Michael J. ;
Campbell, Preston W., III .
JOURNAL OF PEDIATRICS, 2008, 153 (02) :S4-S14
[8]   Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood [J].
Gilljam, M ;
Ellis, L ;
Corey, M ;
Zielenski, J ;
Durie, P ;
Tullis, DE .
CHEST, 2004, 126 (04) :1215-1224
[9]   Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein [J].
Illek, B ;
Zhang, L ;
Lewis, NC ;
Moss, RB ;
Dong, JY ;
Fischer, H .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1999, 277 (04) :C833-C839
[10]   Pharmacologic therapy for stop mutations: how much CFTR activity is enough? [J].
Kerem, E .
CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (06) :547-552